180 Life Sciences Corporate Media Kit

23 Pre-clinical efficacy Lead identified Lead optimisation Clinical development For smoking cessation induced UC a7nAChr Pipeline* 2020 2021 2022 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 *Based on current proposals. No regulatory approvals sought from appropriate authorities at this time. 180 Life Sciences Corp. www.180lifesciences.com Q4 2020